Literature DB >> 25380583

Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease.

Yaroslau Compta1, Tony Valente, Josep Saura, Bàrbara Segura, Álex Iranzo, Mònica Serradell, Carme Junqué, Eduard Tolosa, Francesc Valldeoriola, Esteban Muñoz, Joan Santamaria, Ana Cámara, Manel Fernández, Juan Fortea, Mariateresa Buongiorno, José Luis Molinuevo, Núria Bargalló, María José Martí.   

Abstract

High-oligomeric and low-total-α-synuclein cerebrospinal fluid (CSF) levels have been found in Parkinson's disease (PD), but with inconsistent or limited data, particularly on their clinical and structural correlates in earliest (premotor) or latest (dementia) PD stages. We determined CSF oligomeric- and total-α-synuclein in 77 subjects: 23 with idiopathic REM-sleep behaviour disorder (iRBD, a condition likely to include a remarkable proportion of subjects in the premotor stage of PD) and 41 with PD [21 non-demented (PDND) + 20 demented (PDD)], intended to reflect the premotor-motor-dementia PD continuum, along with 13 healthy controls. The study protocol also included the Unified PD Rating Scale motor-section (UPDRS-III), mini mental state examination (MMSE), neuropsychological cognitive testing, 3T brain MRI for cortical-thickness analyses, CSF τ and CSF Aβ. CSF oligomeric-α-synuclein was higher in PDND than iRBD and in PDD than iRBD and controls, and correlated with UPDRS-III, MMSE, semantic fluency and visuo-perceptive scores across the proposed premotor-motor-dementia PD continuum (iRBD + PDND + PDD). CSF total-α-synuclein positively correlated with age, CSF Aβ, and, particularly, CSF τ, tending towards lower levels in PD (but not iRBD) vs. controls only when controlling for CSF τ. Low CSF total-α-synuclein was associated with dysfunction in phonetic-fluency (a frontal-lobe function) in PD and with frontal cortical thinning in iRBD and PDND independently of CSF τ. Conversely, the associations of high (instead of low) CSF total-α-synuclein with posterior-cortical neuropsychological deficits in PD and with posterior cortical thinning in PDD were driven by high CSF τ. These findings suggest that CSF oligomeric- and total-α-synuclein have different clinical, neuropsychological and MRI correlates across the proposed premotor-motor-dementia PD continuum. CSF total-α-synuclein correlations with CSF τ and Aβ support the hypothesis of an interaction among these proteins in PD, with CSF τ probably influencing the presence of high (instead of low) CSF total-α-synuclein and its correlates mostly in the setting of PD-related dementia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25380583     DOI: 10.1007/s00415-014-7560-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  43 in total

1.  Spanish Multicenter Normative Studies (NEURONORMA Project): norms for the Rey-Osterrieth complex figure (copy and memory), and free and cued selective reminding test.

Authors:  Jordi Peña-Casanova; Nina Gramunt-Fombuena; Sonia Quiñones-Ubeda; Gonzalo Sánchez-Benavides; Miquel Aguilar; Dolors Badenes; José Luis Molinuevo; Alfredo Robles; Maria Sagrario Barquero; María Payno; Carmen Antúnez; Carlos Martínez-Parra; Anna Frank-García; Manuel Fernández; Verónica Alfonso; Josep M Sol; Rafael Blesa
Journal:  Arch Clin Neuropsychol       Date:  2009-08-06       Impact factor: 2.813

Review 2.  What's wrong with Bonferroni adjustments.

Authors:  T V Perneger
Journal:  BMJ       Date:  1998-04-18

3.  Phosphorylated α-synuclein in Parkinson's disease.

Authors:  Yu Wang; Min Shi; Kathryn A Chung; Cyrus P Zabetian; James B Leverenz; Daniela Berg; Karin Srulijes; John Q Trojanowski; Virginia M-Y Lee; Andrew D Siderowf; Howard Hurtig; Irene Litvan; Mya C Schiess; Elaine R Peskind; Masami Masuda; Masato Hasegawa; Xiangmin Lin; Catherine Pan; Douglas Galasko; David S Goldstein; Poul Henning Jensen; Hui Yang; Kevin C Cain; Jing Zhang
Journal:  Sci Transl Med       Date:  2012-02-15       Impact factor: 17.956

4.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

5.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

6.  In vivo demonstration that alpha-synuclein oligomers are toxic.

Authors:  Beate Winner; Roberto Jappelli; Samir K Maji; Paula A Desplats; Leah Boyer; Stefan Aigner; Claudia Hetzer; Thomas Loher; Marçal Vilar; Silvia Campioni; Christos Tzitzilonis; Alice Soragni; Sebastian Jessberger; Helena Mira; Antonella Consiglio; Emiley Pham; Eliezer Masliah; Fred H Gage; Roland Riek
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-15       Impact factor: 11.205

7.  Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study.

Authors:  Alex Iranzo; Eduard Tolosa; Ellen Gelpi; José Luis Molinuevo; Francesc Valldeoriola; Mónica Serradell; Raquel Sanchez-Valle; Isabel Vilaseca; Francisco Lomeña; Dolores Vilas; Albert Lladó; Carles Gaig; Joan Santamaria
Journal:  Lancet Neurol       Date:  2013-04-03       Impact factor: 44.182

8.  The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years.

Authors:  Mariese A Hely; Wayne G J Reid; Michael A Adena; Glenda M Halliday; John G L Morris
Journal:  Mov Disord       Date:  2008-04-30       Impact factor: 10.338

9.  Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort.

Authors:  Tessandra Stewart; Changqin Liu; Carmen Ginghina; Kevin C Cain; Peggy Auinger; Brenna Cholerton; Min Shi; Jing Zhang
Journal:  Am J Pathol       Date:  2014-03-11       Impact factor: 4.307

Review 10.  Evolution of cognitive dysfunction in an incident Parkinson's disease cohort.

Authors:  C H Williams-Gray; T Foltynie; C E G Brayne; T W Robbins; R A Barker
Journal:  Brain       Date:  2007-05-29       Impact factor: 13.501

View more
  28 in total

Review 1.  CSF Biomarkers for Early Diagnosis of Synucleinopathies: Focus on Idiopathic RBD.

Authors:  Claudio Liguori; Federico Paolini Paoletti; Fabio Placidi; Roberta Ruffini; Giulia Maria Sancesario; Paolo Eusebi; Nicola Biagio Mercuri; Lucilla Parnetti
Journal:  Curr Neurol Neurosci Rep       Date:  2019-01-14       Impact factor: 5.081

2.  CCAAT/enhancer binding protein δ is a transcriptional repressor of α-synuclein.

Authors:  Tony Valente; Guido Dentesano; Mario Ezquerra; Ruben Fernandez-Santiago; Jonatan Martinez-Martin; Edurne Gallastegui; Carla Domuro; Yaroslau Compta; Maria J Martí; Oriol Bachs; Leonardo Márquez-Kisinousky; Marco Straccia; Carme Solà; Josep Saura
Journal:  Cell Death Differ       Date:  2019-06-17       Impact factor: 15.828

3.  APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease.

Authors:  Thomas F Tropea; Sharon X Xie; Jacqueline Rick; Lana M Chahine; Nabila Dahodwala; Jimit Doshi; Christos Davatzikos; Leslie M Shaw; Vivianna Van Deerlin; John Q Trojanowski; Daniel Weintraub; Alice S Chen-Plotkin
Journal:  Mov Disord       Date:  2017-11-23       Impact factor: 10.338

Review 4.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

5.  Brain atrophy in Parkinson's disease with polysomnography-confirmed REM sleep behavior disorder.

Authors:  Shady Rahayel; Malo Gaubert; Ronald B Postuma; Jacques Montplaisir; Julie Carrier; Oury Monchi; David Rémillard-Pelchat; Pierre-Alexandre Bourgouin; Michel Panisset; Sylvain Chouinard; Sven Joubert; Jean-François Gagnon
Journal:  Sleep       Date:  2019-06-11       Impact factor: 5.849

6.  The prion hypothesis of Parkinson's disease.

Authors:  Yaping Chu; Jeffrey H Kordower
Journal:  Curr Neurol Neurosci Rep       Date:  2015-05       Impact factor: 5.081

Review 7.  Sleep, cerebrospinal fluid, and the glymphatic system: A systematic review.

Authors:  Pearlynne L H Chong; Dea Garic; Mark D Shen; Iben Lundgaard; Amy J Schwichtenberg
Journal:  Sleep Med Rev       Date:  2021-11-18       Impact factor: 11.609

8.  Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease.

Authors:  Nour K Majbour; Nishant N Vaikath; Karin D van Dijk; Mustafa T Ardah; Shiji Varghese; Louise B Vesterager; Liliana P Montezinho; Stephen Poole; Bared Safieh-Garabedian; Takahiko Tokuda; Charlotte E Teunissen; Henk W Berendse; Wilma D J van de Berg; Omar M A El-Agnaf
Journal:  Mol Neurodegener       Date:  2016-01-19       Impact factor: 14.195

9.  Ultrasensitive Detection of Aggregated α-Synuclein in Glial Cells, Human Cerebrospinal Fluid, and Brain Tissue Using the RT-QuIC Assay: New High-Throughput Neuroimmune Biomarker Assay for Parkinsonian Disorders.

Authors:  Sireesha Manne; Naveen Kondru; Monica Hepker; Huajun Jin; Vellareddy Anantharam; Mechelle Lewis; Xuemei Huang; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  J Neuroimmune Pharmacol       Date:  2019-01-31       Impact factor: 4.147

Review 10.  Cognitive Impairment in Parkinson's Disease: Epidemiology, Clinical Profile, Protective and Risk Factors.

Authors:  Paulina Gonzalez-Latapi; Ece Bayram; Irene Litvan; Connie Marras
Journal:  Behav Sci (Basel)       Date:  2021-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.